Elucidation of the molecular determinants for an agonist to bind and activate its receptor is a critical process in the understanding of the regulation of cellular activities by circulating soluble factors. The largest group of membrane receptors now recognized is the superfamily of guanine nucleotide-binding protein (G protein) 1 -coupled receptors (1), which includes diverse families with distinct themes for ligand binding (2). These themes correlate with the size and physicochemical characteristics of the pharmacophoric domains of the natural ligands, as well as with the structural features of the receptors themselves (2). The secretin receptor family was recently recognized as a distinct family within this superfamily, which binds moderate sized peptides having diffuse pharmacophoric domains (3). A key structural feature of this family is a long extracellular N terminus containing six conserved cysteine residues (3).
, and Thr 261 ) in the N-terminal half of the second loop as providing critical determinants. All receptor constructs which expressed sensitive cAMP responses to secretin (EC 50 <5 nM) bound this peptide with high affinity. Of note, one construct dissociated high affinity binding of secretin from its biological responsiveness, providing a clue to the conformational "switch" that activates this receptor.
Elucidation of the molecular determinants for an agonist to bind and activate its receptor is a critical process in the understanding of the regulation of cellular activities by circulating soluble factors. The largest group of membrane receptors now recognized is the superfamily of guanine nucleotide-binding protein (G protein) 1 -coupled receptors (1) , which includes diverse families with distinct themes for ligand binding (2) . These themes correlate with the size and physicochemical characteristics of the pharmacophoric domains of the natural ligands, as well as with the structural features of the receptors themselves (2) . The secretin receptor family was recently recognized as a distinct family within this superfamily, which binds moderate sized peptides having diffuse pharmacophoric domains (3) . A key structural feature of this family is a long extracellular N terminus containing six conserved cysteine residues (3).
Indeed, this N-terminal domain has been shown to be important for the binding of ligands to the secretin receptor family, with deletions and critical site mutants losing key binding and activation properties (4 -7) . Our recent work with chimeric secretin/VIP receptor constructs was consistent with this theme, supporting a critical role for the receptor N terminus in determining its structural specificity (8) . The binding and biological activity properties of the wild type VIP receptor could be reproduced by a chimeric receptor with the predicted extracellular N terminus of the VIP receptor attached to the remainder of the secretin receptor. Of particular interest, the converse was not true (8) . While the secretin receptor N terminus was also critical, it was not sufficient in contributing the necessary determinants for high affinity secretin binding and activation. In that report, two constructs which provided both the secretin receptor N terminus and an additional domain provided the necessary determinants for these activities. These additional domains represented the first extracellular loop in one construct and the remainder of the secretin receptor exclusive of that loop in the other construct.
In the present study, we have extended our previous work to further identify critical determinants for secretin receptor function. For this we have continued to construct and study secretin/VIP receptor chimeras, with the secretin receptor sequence domains representing progressively smaller segments. This has established that, like the first extracellular loop previously identified, the second extracellular loop provided important determinants to complement the secretin receptor N terminus. Within these two domains, we have been able to further define two residues in the C-terminal half of the first loop (His  189 and Lys   190 ) and four residues in the N-terminal half of the second loop (Phe which contain critical determinants for secretin binding and activation. We have also gained additional insights into specific regions of the N terminus of the secretin receptor which are important. Critical determinants are present in the first 10 N-terminal residues and within the half of this domain adjacent to the plasmalemma.
In this series of chimeric receptors, every construct that exhibited cAMP responsiveness to nanomolar concentrations of secretin, also bound secretin with high affinity. Of particular interest, there was one of this series of constructs which bound secretin with high affinity, while not eliciting a cAMP response. This important dissociation of binding and activation might provide insight into induction of a conformational switch that activates this receptor.
MATERIALS AND METHODS
The rat secretin receptor cDNA was previously cloned and characterized (9, 10) , and the rat VIP receptor cDNA was kindly provided by Professor Nagata (Osaka Bioscience Institute, Osaka, Japan) (11) . Rat secretin-27, the secretin analogue, [Tyr 10 ,pNO ]secretin-27, and VIP were synthesized in our laboratory, using techniques we have previously described (10) . Enzymes for mutagenesis were purchased from Boehringer Mannheim, except for BsrGI and SpeI, which were from New England Biolabs. All other reagents were analytical grade.
Receptor Constructs-The receptor mutants studied in this work represented chimeric constructs of wild type rat secretin and VIP receptors (see Figs. 1-4 ). Chimeras were designed to replace portions of one wild type receptor cDNA with the corresponding portions of the other receptor. Mutagenesis strategies included utilization of ligations at naturally occurring restriction sites, polymerase chain reaction (PCR) overlap extensions (12) , and applications of the method of Kunkel (13) .
Receptor constructs were built in the eukaryotic expression vector, pBK-CMV (Stratagene, La Jolla, CA). The wild type secretin receptor cDNA was inserted into the BamHI and HindIII sites, and the wild type VIP receptor cDNA was inserted into the HindIII site. The nomenclature for the chimeras utilizes e 1 , e 2 , e 3 , and e 4 as the predicted N terminus and first, second, and third extracellular loop domains, with amino acid residues identified by number, according to the numbering schemes of the wild type receptors (9, 11) . Numbers not specifically attributed to the VIP receptor (i.e. following a "V") correspond to numbers of secretin receptor (S) residues.
Se 1 V was generated by PCR mutagenesis, as described previously (8) . V(1-45)S was produced by overlap extension. Initial PCR products represented the 5Ј-end of the VIP receptor sequence through codon 45, and secretin receptor sequence representing codons 62 through 149. These were purified, used in a round of PCR overlap extension, and cut with BamHI and BsrGI. The resultant fragment was then ligated into the wild type secretin receptor cDNA construct which was similarly prepared.
S(1-10)V(7-45)S was also prepared by overlap extension, this time using the V(1-45)S construct and wild type secretin receptor construct as templates. The overlap provided replacement of VIP receptor codons 1 through 7 with the corresponding secretin receptor codons 1 through 10.
S(1-10)V was generated using the Kunkel (13) method. An 87-oligomer was designed to replace the VIP receptor codons 1-7 with the corresponding secretin receptor codons 1-10. Simultaneous mutagenesis with a second oligo introduced a silent BsrGI site at position 116 of the VIP receptor, to allow for subsequent mutagenesis by restriction digestion.
S(1-10)V(7-117)S was produced by replacing the BsrGI-HindIII fragment of the S(1-10)V construct with the corresponding fragment of the wild type secretin receptor construct. (13), using appropriate mutagenesis oligos. The single-stranded template for this was produced from the Se 1 V construct, representing secretin receptor codons 1 through 123 and VIP receptor codons 116 through 429.
All PCR reactions were performed in a thermocycler with Taq DNA polymerase running 35 cycles: 94°C for 1 min, 55°C for 2 min, and 72°C for 3 min. PCR and restriction digestion products were separated on 1% agarose gels and purified on Qiaex resin. Transformation of receptor constructs was performed in XLI-Blue MRFЈ cells. Proper mutagenesis was confirmed by direct DNA sequencing, using the method of Sanger et al. (14) .
Receptor Expression-COS-7 cells (American Type Culture Collection) served as the expression system for the receptor constructs. Cells were maintained in culture in Dulbecco's modified Eagle's medium with 5% Fetal Clone 2 (HyClone Laboratories, Logan, UT), and transfected with 2-4 g of DNA. For this, a protocol based on the DEAE-dextran method was used including dimethyl sulfoxide shock and treatment with 0.1 mM chloroquine diphosphate (8, 15) . Cells were harvested mechanically 72 h after transfection for subsequent studies.
Biological Activity Studies-The biological activity of our receptor constructs was assessed by their ability to elicit intracellular cAMP generation in response to agonist stimulation. Transfected COS cells were harvested mechanically, washed in phosphate-buffered saline, and resuspended in Krebs-Ringer-HEPES (KRH) medium containing 25 mM HEPES, pH 7.4, 104 mM NaCl, 5 mM KCl, 1.2 mM MgSO 4 , 2 mM CaCl 2 , 1 mM KH 2 PO 4 , 0.2% bovine serum albumin, and 0.01% soybean trypsin inhibitor, which was supplemented with 1 mM 3-isobutyl-1-methylxanthine. Cells were stimulated with peptide for 10 min at 37°C, and lysed by vortexing after the addition of ice-cold 6% perchloric acid. The pH was adjusted to 6 with KHCO 3 , and lysates were cleared by centrifugation at 2000 rpm for 10 min. Supernatants were used for determination of cAMP levels with a [ 3 H]cAMP kit from Diagnostic Products Corp. (Los Angeles, CA), following the manufacturer's instructions. Assays were performed in duplicate and repeated in at least three independent experiments. Radioactivity was quantified in a Beckman LS6000 scintillation counter.
Ligand Binding Studies-For binding studies, receptor-bearing COS cell membranes were prepared 72 h after transfection, as described previously (10) . Radioligands were prepared by oxidative radioiodination of the secretin analogue, [Tyr 10 ,pNO ]secretin-27, and VIP, with purification by reversed-phase high peformance liquid chromatography to specific radioactivities of 2000 Ci/mmol, as we described elsewhere (10) . Incubations included 1-10 g of relevant receptor-bearing membranes with a constant amount of radiolabeled ligand (3-5 pM), and increasing concentrations of analogous unlabeled ligand for 1 h at room temperature in KRH medium. Free radioligand was then removed by rapid filtration and washing using a Skatron cell harvester with glass fiber filter mats that had been presoaked in 0.3% polybrene. Nonspecific binding was determined in the presence of excess unlabeled analogous peptide (1 M secretin and 0.1 M VIP).
Statistical Analysis-All observations were repeated at least three times in independent experiments and are expressed as means Ϯ S.E. For analysis of binding data, the Prism software package (GraphPad Software, San Diego, CA) was applied using the nonlinear regression analysis routine for radioligand binding. Differences were determined by using the Mann-Whitney test for unpaired values, with p Ͻ 0.05 considered to be significant.
RESULTS
This work explores the secretin receptor determinants that are critical for ligand binding and the resultant stimulation of signaling cascades. This represents a direct extension of our previous work (8) which also utilized secretin/VIP receptor chimeras, but in which we exchanged much larger domains. Here, we have focused on subdomains within the extracellular N terminus and within each of the extracellular loop regions. Biological activity data are illustrated in Figs. 1-4 , and are summarized along with binding data in Table I . Constructs were expressed at similar levels, based on radioligand binding analysis (17 Ϯ 7 pmol/mg of protein) and the quantitative increases in cAMP stimulated by agonists.
The wild type secretin receptor responded to stimulation by increasing intracellular cAMP, with EC 50 values of 1.6 Ϯ 0.4 nM secretin and 218 Ϯ 109 nM VIP. This represents a selectivity of 2 orders of magnitude for this receptor's native ligand. The chimeric receptor that incorporated the extracellular N terminus of the secretin receptor with the remainder corresponding to the VIP receptor (Se 1 V) lost its selectivity for secretin. It was less responsive to secretin than the wild type receptor (EC 50 ϭ 33 Ϯ 3 nM; p ϭ 0.01), while maintaining its responsiveness to VIP (EC 50 ϭ 45 Ϯ 9 nM; p ϭ 0.1). These results provided the basis for identifying additional determinants which were necessary to complement the extracellular N terminus of the secretin receptor in ligand recognition (Fig. 1) .
Critical Determinants in the First Extracellular Loop Region of the Secretin Receptor-Replacement of the N-terminal half of the first loop region of Se 1 V with the corresponding sequence of the secretin receptor (Se 1 e 2 (179 -185)V) did not improve secretin responsiveness (EC 50 ϭ 25 Ϯ 8 nM; p ϭ 0.4 relative to the Se 1 V construct) (Fig. 2) . Of note, despite low responsiveness to secretin, this construct bound secretin with the same high affinity (K i ϭ 1.3 Ϯ 0.1 nM) as was observed for the wild type secretin receptor (K i ϭ 2.2 Ϯ 0.7 nM; p ϭ 0.4). High affinity binding to this receptor construct was thus dissociated from biological responsiveness.
Complementation of the secretin receptor N terminus with the C-terminal half of the first loop region in the Se 1 e 2 (184 -190)V construct substantially improved responsiveness to secretin (EC 50 ϭ 3.3 Ϯ 0.4 nM; p ϭ 0.03 relative to the Se 1 construct), such that it was not statistically different from the wild type secretin receptor (p ϭ 0.1) (Fig. 2) . VIP stimulated cAMP responses in this construct with an EC 50 of 157 Ϯ 72 nM. This construct also displayed high affinity binding of secretin, not different from that for the wild type secretin receptor (K i ϭ 3.1 Ϯ 0.3 nM; p ϭ 0.1).
The critical contribution of the C-terminal half of the first loop region to secretin recognition appears to be dependent on two basic residues, His 189 and Lys
190
. Insertion of these two residues at codon position 183 of the VIP receptor portion of Se 1 V, resulting in the Se 1 e 2 (189, 190)V construct, was also able to improve responsiveness to secretin (EC 50 ϭ 4.5 Ϯ 0.6 nM; p ϭ 0.01 relative to the Se 1 V construct) (Fig. 2) . Responsiveness to VIP was unaltered (EC 50 ϭ 65 Ϯ 11 nM). Secretin bound to this construct with high affinity (K i ϭ 1.6 Ϯ 0.3 nM). Interestingly, insertion of only one basic residue (Lys 190 ) at this same position in the Se 1 e 2 (190)V construct had no effect on secretin responsiveness (EC 50 ϭ 24 Ϯ 3 nM, p ϭ 0.1 relative to the Se 1 V construct) (Fig. 2) .
Critical Determinants in the Extracellular Second and Third Loop Regions-Successful complementation of the extracellular N terminus of the secretin receptor could also be achieved by replacement of determinants in the second extracellular loop region of the secretin receptor. Replacement of the entire second loop region in addition to the extracellular N terminus in the Se 1 e 3 V construct resulted in an EC 50 of 3.5 Ϯ 0.6 nM secretin (Fig. 3) . This represented a 10-fold improvement compared to the Se 1 V construct (p ϭ 0.01), and secretin responsiveness was not different from that of the wild type receptor (p ϭ 0.1). VIP stimulated cAMP responses with an EC 50 of 80 Ϯ 15 nM. Consistent with its biological activity, Se 1 e 3 V bound secretin with high affinity (K i ϭ 1.4 Ϯ 0.6 nM).
Sequential bisection of this domain revealed that the critical determinants for recognition of secretin were located in the N-terminal half of the second loop. The effect seen by replacement of the entire loop region could be mimicked by incorporation of four secretin receptor-specific residues (Phe, Leu, Asn, Thr) in the Se 1 e 3 (257,258,260,261)V construct. This construct responded to secretin with an EC 50 of 4.9 Ϯ 0.1 nM (p ϭ 0.1 compared to Se 1 e 3 V) (Fig. 3) . Cyclic AMP responses to VIP were unaltered (EC 50 ϭ 93 Ϯ 44 nM). Binding of secretin occurred with a K i of 1.6 Ϯ 0.2 nM. Conversely, the C-terminal half of the second loop was not capable of complementing the extracellular N terminus. Replacement of the relevant three residues in that domain in the Se 1 e 3 (266 -268)V construct did not improve responsiveness to secretin (EC 50 ϭ 95 Ϯ 48 nM; p ϭ 0.2 relative to the Se 1 V construct) (Fig. 3) . When the third loop region of the Se 1 V was changed to secretin receptor-specific sequence in the Se 1 e 4 V construct, no effect was seen in secretin responsiveness which remained low (EC 50 ϭ 147 Ϯ 50 nM) (Fig. 3) .
Critical Determinants in the Extracellular N Terminus of the Secretin Receptor-We previously showed the critical role of this domain for ligand specificity (8) and now wanted to better localize critical portions within this domain. Replacement of half of the N terminus of the secretin receptor with the analogous 45 residues of the VIP receptor in the V(1-45)S construct resulted in a marked reduction of secretin responsiveness (EC 50 ϭ 74 Ϯ 21 nM) compared to the wild type secretin receptor (p ϭ 0.01) (Fig. 4) , and resulted in loss of saturable secretin binding. The portion of the VIP receptor incorporated in this construct alone was also unable to provide high responsiveness to VIP (EC 50 ϭ 148 Ϯ 48 nM).
Of note, reincorporation of the N-terminal 10 secretin receptor specific residues in the S(1-10)V(7-45)S construct resulted in almost full responsiveness to secretin (EC 50 ϭ 3.2 Ϯ 0.5 nM secretin) (Fig. 4) , while responsiveness to VIP remained low (EC 50 303 Ϯ 203 nM). While important, this small domain of the secretin receptor was not sufficient by itself to recognize secretin. The S(1-10)V construct displayed low responsiveness to secretin (EC 50 ϭ 675 Ϯ 48 nM) (Fig. 4) , with no saturable binding of secretin. This construct, however, responded well to VIP stimulation (EC 50 ϭ 2.2 Ϯ 0.5 nM).
It was also not possible to recover secretin responsiveness through complementation of the N-terminal 10 residues, incorporated in the S(1-10)V construct, with the secretin receptor trunk that comprised all loop regions of this receptor proven to contribute to ligand recognition. The resulting construct, S(1-10)V(7-117)S, retained its low responsiveness to secretin (EC 50 ϭ 81 Ϯ 11 nM). When the inability of this construct to recognize secretin is contrasted with the S(1-10)V(7-45)S construct, it is clear that the portion of the secretin receptor in the N terminus adjacent to the plasma membrane also contains determinants critical for secretin recognition. Fig. 5 shows direct competition-binding data for key chimeric receptor constructs. These represent those constructs which resulted in sensitive responsiveness to secretin by providing both the N terminus and critical loop domains of the secretin receptor. Also shown are data for the construct which bound secretin with high affinity, but did not have a sensitive biological response to this hormone (Se 1 e 2 (179 -185)V) . DISCUSSION Increasing evidence suggests that the sites which best discriminate ligand-receptor interactions in the recently discovered secretin receptor family are located in the extracellular portions of these receptors, reflecting the characteristic structural features of these receptors and the distinct properties of their peptide ligands (3). In our recent study of chimeric secretin/VIP receptors, we demonstrated the pivotal role of the extracellular N terminus of these receptors for ligand specificity (8) . In the secretin receptor, however, this domain was not sufficient by itself to provide full specificity and sensitivity to secretin. In the chimeric constructs, this domain had to be complemented by other secretin receptor-specific determinants. There was, however, redundancy among the receptor determinants that were able to effectively complement the extracellular N terminus. Identification of this was only possible using chimeric receptor constructs. The high degree of structural homology between the receptors for secretin and VIP, having clearly distinct ligand specificity, provided the basis for this approach. Such chimeric constructs may be more likely to fold properly on the cell surface and to maintain their functional conformations than approaches involving receptor mutations such as deletions or replacements with nonconserved residues. The chimeric approach may also reduce the likelihood of allosteric artifacts interfering with receptor-ligand interaction, and may provide an opportunity to identify receptor determinants directly involved in ligand discrimination.
In the present work we extended our previous studies (8) and directed our attention to the elucidation of those determinants that were able to complement the extracellular N terminus of the secretin receptor for ligand recognition. Only 12 residues in the first loop region were potential candidates for contributing to secretin specificity. Sequential bisections and site mutant construction revealed that a sequence of two basic residues, His 189 and Lys
, but not one of them alone, in the C-terminal half of the first loop region was capable of complementing the N terminus of the secretin receptor in recognizing the native ligand. Evidence exists that an acidic residue in the center of the secretin peptide (Asp discrimination.
With this series of constructs we can clearly demonstrate that the determinants that provide secretin receptor specificity are located in extracellular portions of the receptor molecule. However, it would be too simplistic to conclude that ligand interaction with the receptor is confined to these domains. Residues which are conserved between the secretin and VIP receptors, will by definition not contribute to ligand specificity, however, they are likely to contribute key structural features to the receptor conformation, and some could also be involved in ligand binding and receptor activation.
We also focussed on the extracellular N terminus of the secretin receptor, which was previously demonstrated to be important (8) , trying to more specifically identify critical regions within this domain. A large region in the half of the N terminus most distal from the plasmalemma could be replaced without effect, but the presence of the first 10 residues at the distal end of this region was necessary to recognize secretin. Critical determinants also seem to be present within the other half of the secretin receptor N terminus, because the first 10 residues alone were not able to provide full secretin responsiveness, even when complemented with the secretin receptorspecific loop regions. Interestingly, deletional mutagenesis of the corresponding portions in the parathyroid hormone receptor showed critical effects on cell surface expression of that receptor (6) .
One of the chimeric constructs in which the extracellular N terminus of the secretin receptor was complemented with the N-terminal half of the secretin receptor first extracellular loop, while the rest of the construct represented VIP receptor sequence (Se 1 e 2 (179 -185)V), did not show high responsiveness to secretin. However, this construct bound secretin with the same high affinity as the wild type secretin receptor. The dissociation of receptor activation from high affinity binding is a characteristic feature of antagonists and has supported the concept that ligand binding and receptor activation are separate and distinct events. Activation likely requires a highly specific conformational change in the receptor. The finding in this chimeric construct is particularly interesting, since it demonstrates the dissociation of these two events for a naturally occurring agonist. This observation might provide a valuable clue as to how high affinity binding of agonist ligand and the subsequent induction of the conformational switch that activates the receptor, could be structurally related in the secretin receptor.
